Vabysmo Real-World Data Show Durable Vision Gains Across Retinal Diseases
Tom Rudovsky · Reported by BusinessWire
More coverage: Healthcare
Sentiment
Positive
Importance
7
Price
$51.88
Mkt Cap
$334.884B
52W Low
$40.05
52W High
$60.85
52W Position
30% above low
Off High
15% below high
Rel. Volume
0.6× avg
Market data snapshot near publication time
RHHBY sits 30% above its 52-week low of $40.05.
Summary
Genentech presented VOYAGER study data at EURETINA 2026 showing Vabysmo's real-world effectiveness across wet AMD, DME, and RVO. Vision gains and anatomical improvements were consistent with Phase III results, with treatment intervals extending in months 7-12. The data reinforce Vabysmo's commercial positioning in a competitive ophthalmology market.
At the time of this announcement, RHHBY was trading at $51.88 on OTC in the Life Sciences sector, with a market capitalization of approximately $334.9B. The 52-week trading range was $40.05 to $60.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.
Price Chart
RHHBY - Latest Insights
RHHBY
Oct 25, 2026, 11:30 AM EDT
Price at Filing:
$61.17
Real-time Price:
$59.45
Change:
-$1.72 (-3%)
Market Cap:
$386.097B
RHHBY
Oct 23, 2026, 1:30 PM EDT
Price at Filing:
$60.19
Real-time Price:
$59.45
Change:
-$0.740 (-1%)
Market Cap:
$386.097B
RHHBY
Oct 22, 2026, 12:50 PM EDT
Price at Filing:
$59.48
Real-time Price:
$59.45
Change:
-$0.030 (-0.05%)
Market Cap:
$386.097B
RHHBY
Oct 16, 2026, 1:00 AM EDT
Price at Filing:
$56.78
Real-time Price:
$59.45
Change:
+$2.67 (+5%)
Market Cap:
$386.097B
RHHBY
Oct 10, 2026, 5:40 PM EDT
Price at Filing:
$54.09
Real-time Price:
$59.45
Change:
+$5.36 (+10%)
Market Cap:
$386.097B